Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy

Scandinavian Journal of Rheumatology

Volumn 37, Issue 4, 2008, Pages 306-309

  Sommer, W H ^a,b   Ganiere, V ^b   Gachoud, D ^b   Keta, A ^b   Abou Hajar, A ^b   Dudler, J ^b   Aujesky, D ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PREDNISONE;

AGED; ARTICLE; BRONCHOSCOPY; CASE REPORT; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HUMAN; LABORATORY TEST; LUMBAR PUNCTURE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; METHOTREXATE; NEUROTOXICITY SYNDROMES; PNEUMONIA;

EID: 46949109031     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740801908001     Document Type: Article

References (15)

1. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
2. Rollins N, Winick N, Bash R, Booth T. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol 2004;25:1688-95.
3. Sandoval C, Kutscher M, Jayabose S, Tenner M. Neurotoxicity of intrathecal methotrexate: MR imaging findings. AJNR Am J Neuroradiol 2003;24:1887-90.
4. Szawarski P, Chapman CS. A woman who couldn't speak: report of methotrexate neurotoxicity. Postgrad Med J 2005;81:194-5.
5. Aplin CG, Russell-Jones R. Acute dysarthria induced by low dose methotrexate therapy in a patient with erythrodermic cutaneous T-cell lymphoma: an unusual manifestation of neurotoxicity. Clin Exp Dermatol 1999;24:23-4.
6. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004;43:143-7.
7. Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. Q J Med 2001;94:309-19.
8. Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - a Pediatric Oncology Group Study. J Clin Oncol 1998;16:1712-22.
9. Lo Nigro L, Di Cataldo A, Schiliro G. Acute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols. Med Pediatr Oncol 2000;35:449-55.
10. Morita Y, Fukazawa T, Hirashima M, Kaga K, Kusaoi M, Morita T, et al. The effect of methotrexate (MTX) on expression of signalling lymphocytic activationmolecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production. Scand J Rheumatol 2006;35:268-72.
11. Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003;49:92-104.
12. Renard D, Westhovens R, Vandenbussche E, Vandenberghe R. Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol 2004;251:226-8.
13. Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40:1829-37.
14. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987;14:1164-71.
15. Alarcon GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-lung Study Group. Ann Intern Med 1997;127:356-64.